Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML
1,501 views · Published 11 December 2017 · 6:13 · Indexed 6 November 2026
Channel: American Society of Hematology · 2017 · Nonprofits & Activism
Patients with myelodysplastic syndromes and chronic myelomonocytic leukemia and TET2 mutations have high risks of cardiovascular toxicity, suggesting that these patients might benefit from a cardiac work-up at diagnosis. Dr. Molenaar shares results from this SEER analysis.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding